Mansoor Mirza Biography and Net Worth

Director of Sera Prognostics


Mansoor Raza Mirza, M.D. has served as a member of our Board since December 2014. Dr. Mirza is Chief Oncologist at the Department of Oncology, Rigshopitalet — the Copenhagen University Hospital, Denmark and Medical Director of the Nordic Society of Gynaecological Oncology, or NSGO. Dr. Mirza is Chairman of the European Network of Gynaecological Oncological Trial groups, or ENGOT. Dr. Mirza is both a medical and radiation oncologist, with a primary focus in non-surgical treatment of gynecologic cancers. His key academic goals are to promote clinical research, international trial collaboration and education, and he has broad experience in clinical protocol development, trial conduct and clinical trial regulations. Dr. Mirza is the author of several phase 1, 2 and 3 studies. Several of those studies led to FDA and European Medicines Agency registrations. He serves on several Independent Data Safety Monitoring Committees of international studies. He is an invited speaker at several international conferences, such as “Meet the Professor” at American Society of Clinical Oncology and “Presidential Symposium” at European Society for Medical Oncology. He is the author of global consensus guidelines for the management of ovarian cancer and of European guidelines for the management of several gynecological malignancies. His other current appointments include service as ESGO Council Member (European Society of Gynaecological Oncology), Executive Director of GCIG (Gynecologic Cancer InterGroup), Vice-Chairman of the Danish Gynecological Cancer Society, faculty member of the European Society of Medical Oncology and of ESGO. He also serves on the board of directors of Karyopharm Therapeutics Inc., a public pharmaceutical company and has served as a clinical consultant to Karyopharm Therapeutics Inc. since 2010. He has multiple publications in high-impact journals, including several publications in the New England Journal of Medicine and the Lancet. He holds an M.D., Diploma in Surgery and Diploma in Clinical Oncology from the Pirogov Moscow State Medical Institute as well as post-graduate education and certification in radiation and medical oncology from the University of Southern Denmark. We believe Dr. Mirza’s qualifications to serve on our board include his expertise in gynecologic cancers, and his knowledge of our company and its business through service on our board since December 2014.

What is Mansoor Raza Mirza's net worth?

The estimated net worth of Mansoor Raza Mirza is at least $119.52 thousand as of December 5th, 2025. Dr. Mirza owns 57,740 shares of Sera Prognostics stock worth more than $119,522 as of September 18th. This net worth evaluation does not reflect any other assets that Dr. Mirza may own. Learn More about Mansoor Raza Mirza's net worth.

How do I contact Mansoor Raza Mirza?

The corporate mailing address for Dr. Mirza and other Sera Prognostics executives is 2749 E. Parleys Way, Suite 200, Salt Lake City, UT, 84109. Sera Prognostics can also be reached via phone at 801-990-0520 and via email at [email protected]. Learn More on Mansoor Raza Mirza's contact information.

Has Mansoor Raza Mirza been buying or selling shares of Sera Prognostics?

Mansoor Raza Mirza has not been actively trading shares of Sera Prognostics over the course of the past ninety days. Most recently, Mansoor Raza Mirza sold 292 shares of the business's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $3.05, for a transaction totalling $890.60. Following the completion of the sale, the director now directly owns 57,740 shares of the company's stock, valued at $176,107. Learn More on Mansoor Raza Mirza's trading history.

Who are Sera Prognostics' active insiders?

Sera Prognostics' insider roster includes Austin Aerts (Strategic Advisor), John Boniface (Chief Scientific Officer​), Benjamin Jackson (General Counsel), Paul Kearney (Data Science Advisor), Sandra Lawrence (Director), Mansoor Mirza (Director), and Joshua Phillips (Director). Learn More on Sera Prognostics' active insiders.

Are insiders buying or selling shares of Sera Prognostics?

In the last twelve months, insiders at the sold shares 39 times. They sold a total of 167,112 shares worth more than $394,436.33. The most recent insider tranaction occured on September, 10th when insider Dyaarl Lee Jr. Anderson sold 1,800 shares worth more than $3,600.00. Insiders at Sera Prognostics own 11.3% of the company. Learn More about insider trades at Sera Prognostics.

Information on this page was last updated on 9/10/2026.

Mansoor Raza Mirza Insider Trading History at Sera Prognostics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/5/2025Sell292$3.05$890.6057,740View SEC Filing Icon  
11/5/2025Sell221$3.04$671.8458,032View SEC Filing Icon  
9/5/2025Sell222$3.35$743.7058,480View SEC Filing Icon  
8/5/2025Sell225$2.50$562.5058,702View SEC Filing Icon  
7/7/2025Sell234$2.36$552.2458,927View SEC Filing Icon  
6/6/2025Sell107$1.58$169.0659,161View SEC Filing Icon  
5/8/2025Sell106$2.44$258.6443,672View SEC Filing Icon  
4/7/2025Sell107$3.35$358.4543,778View SEC Filing Icon  
3/6/2025Sell99$4.16$411.8443,885View SEC Filing Icon  
1/6/2025Sell100$7.69$769.006,536View SEC Filing Icon  
11/11/2024Sell95$7.32$695.406,729View SEC Filing Icon  
10/7/2024Sell96$7.15$686.406,824View SEC Filing Icon  
9/6/2024Sell96$7.16$687.366,920View SEC Filing Icon  
8/7/2024Sell101$7.42$749.427,016View SEC Filing Icon  
See Full Table

Mansoor Raza Mirza Buying and Selling Activity at Sera Prognostics

This chart shows Mansoor Raza Mirza's buying and selling at Sera Prognostics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sera Prognostics Company Overview

Sera Prognostics logo
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $2.07
Low: $2.04
High: $2.08

50 Day Range

MA: $2.05
Low: $1.92
High: $2.27

2 Week Range

Now: $2.07
Low: $1.56
High: $3.95

Volume

7,205 shs

Average Volume

23,442 shs

Market Capitalization

$81.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98